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Abstract 
 Since their discovery in 2007, human induced pluripotent stem (iPS) cells have been 
widely championed as the future for regenerative medicine. 
 By differentiating iPS cells into specialised cells for transplantation, it may be possible 
to replace diseased cells and “cure” patients of various chronic degenerative 
conditions, including Parkinson’s disease. 
 Such putative iPS cell-based therapies would avoid the need to procure 
transplantable cells from (and in the process, destroy) human embryos, and could be 
administered to patients without immunosuppressive therapy. 
 In reality, however, the optimism surrounding iPS cell research has outpaced progress 
to date and likely emanates, in part, from the “moral panic” surrounding human 
embryo research. 
 At such an early stage of development, questions remain about whether iPS cells are 
strictly equivalent to human embryonic stem cells as a source of transplantable cells. 
The Heerey Committee considered this point in its recent review of the 
Commonwealth legislation governing embryo research and human cloning and its 
Report (tabled in federal Parliament in July 2011) recommended that embryonic stem 
cell research should continue in Australia. 
 In addition, there are many ethical issues which will need to be considered when 
enrolling vulnerable patients in trials of iPS cell therapy given the uncertain benefits 
and risks involved. 
 In the rush to embrace iPS cell therapy, there is a real risk that the public may 
overrate the benefits and expect imminent translation to the clinic.  
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Until recently, treatment for chronic degenerative conditions was largely to reduce 
symptoms and improving physiological functioning in the hope of gaining some (often 
limited) increase in life expectancy. For example, pharmacological agents and surgical 
procedures may relieve the symptoms of Parkinson’s disease –muscle rigidity, tremor, 
bradykinesia, and postural instability – caused by the loss of nigrostriatal dopaminergic 
neurons in the midbrain region, but are only effective in the early stages of disease 
progression and may induce serious adverse effects.1 
In the last decade, however, the advent of “regenerative medicine” has raised hope that 
normal structure and function may be restored in these intractable conditions,by harnessing 
pluripotent stem cells – cells that can be converted into all cell types of the human body – to 
produce specialised cells and replace diseased cells in vivo. For instance, dopaminergic 
neurons could be generated from pluripotent stem cells for transplantation in patients with 
Parkinson’s disease. Until recently, however, pluripotent stem cells could only be derived 
from human embryos that are destroyed when harvesting the embryonic stem cells. 
Although these embryos are left over from infertility treatment and would otherwise be 
destroyed, their use for research remains ethically contentious and is governed by tight 
statutory constraints.2 
In 2007, it was discovered that somatic cells (e.g. fibroblasts obtained from patient skin 
biopsies) could be reprogrammed into human pluripotent stem cells – called iPS cells – 
without using, or destroying, human embryos. Certain genes are inserted into somatic cells 
to revert them to an embryonic stem cell-like state.3 Unlike stem cells derived from human 
embryos, iPS cells are derived from patients’ own cells so are more likely to be 
transplantable without the risk of immune rejection. For these reasons, iPS cell therapy has 
been championed as a superior, “ethical” alternative to embryonic stem cell-based 
approaches.  
While iPS cell research holds significant promise, its purported benefits may have been 
overstated by certain religious groups opposed to research involving human embryos, by 
stem cell scientists keen to embrace a technology free of the regulations governing human 
embryo research, and by a patient community willing to believe the rhetoric of scientific 
“advance”. For example, Australians for Ethical Stem Cell Research have labelled iPS cells as 
“functionally identical” to human embryonic stem cells but “ethically uncontentious: it does 
not use women’s eggs and does not create and destroy human embryos”.4 Prominent 
scientists in iPS cell research have said that “the promise of regenerative medicine could 
soon be met”5 and “we could be there in five years time for diseases that are well 
understood, like Parkinson’s.”6The public have seemingly accepted this rhetoric. The 
majority (188 out of 264) of the public submissions to the Heerey Committee, which recently 
reviewed the Commonwealth legislation governing embryo research and human cloning, 
“did not support the use of human embryos for research” and supported the use of iPS cells 
instead.7 And in a recent survey of 1000 Americans, 61% of respondents asserted that all 
public funding for embryonic stem cell research should cease and be redirected towards iPS 
cell research.8 Increasingly, patients are asking clinicians about stem cell therapies, with a 
growing number of Australians attracted by overseas clinics offering unsubstantiated stem 
cell “therapies” (lacking evidence of efficacy or safety) for various chronic diseases – termed 
“stem cell tourism”.9  
However, the public optimism surrounding cell replacement therapies (including with iPS 
cells) disregards the inevitable delays in effective translation to the clinic. Here we consider 
Parkinson’s disease – one of the key candidate diseases for regenerative medicine. While iPS 
cell therapy has been proposed as a potential “cure” for Parkinson’s disease (Figure 1 – 
located at the end of this document) involving the autologous transplantation of midbrain 
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dopaminergic neurons which may integrate into the host brain and restore motor function 
(as demonstrated in animal studies),10 many barriers remain to be overcome before this 
procedure can be adopted in the clinic. Some of these barriers are particularly salient in 
Parkinson’s disease, like obtaining consent and assessing the cognitive status of patients, but 
they are also relevant to other diseases targeted by iPS cell therapy.  
 
Scientific and clinical challenges 
Unlike embryonic stem cells which are harvested directly from human embryos, iPS cell 
technology requires reprogramming somatic cells towards pluripotency. Initially, retroviral 
vectors were used to deliver the pluripotency-inducing transgenes into the somatic cells.3 
However, as retroviral vectors may randomly integrate into the host genome and trigger the 
expression of cancer-promoting genes, scientists have investigated alternative techniques 
like removing transgenes from genomic integration sites once reprogramming is complete, 
delivering the transgenes via non-integrating DNA microcircles, and exposing somatic cells to 
a cocktail of small molecules – approaches which have yielded varying reprogramming 
efficiencies.11 As iPS cell research advances, techniques to produce iPS cells will probably 
become safer and more efficient. However, this also means that reprogramming methods 
are at risk of rapidly becoming obsolete and generating the impetus to initiate clinical trials 
may be difficult. Indeed the field of reprogramming is moving so quickly thataccording to a 
recent study, a patient’s somatic cells may be directly reprogrammed into replacement cells 
of the desired phenotype (e.g. neurons) without the pluripotent intermediary.12  
A challenge that applies to both iPS cell- and embryonic stem cell-based therapies is deriving 
clinical-grade dopaminergic neurons. Exposing pluripotent stem cells to specific growth 
factors successfully induces differentiation into dopaminergic neurons but leaves behind 
contaminating non-dopaminergic cell types in the culture.13 Also, to generate the correct 
type of dopaminergic neuron (i.e. of midbrain phenotype, as implicated in Parkinson’s 
disease), it may be necessary to include an additional cellular feeder layer or over-express 
certain genes important for early midbrain development,14 but it is unclear whether these 
strategies, which were tested on embryonic stem cells, work with iPS cells. Subtle 
differences between iPS cells and embryonic stem cells have been reported at the molecular 
level, as iPS cells may be imprinted with information tracing them back to their cell of 
origin.15 Even after continuous passaging in vitro to attenuate these epigenetic anomalies,16 
iPS cells may still have reduced stability, homogeneity and ability to differentiate into all cell 
types as compared to embryonic stem cells (which possess a more fully “naïve” ground state 
of pluripotency).15 Since grafts containing a low proportion of dopaminergic neurons may 
cause side effects like dyskinesia (sudden switches between mobility and immobility),17 
attaining high purity yields of midbrain dopaminergic neurons is clearly an important pre-
requisite to first-in-human trials. 
Another limitation of iPS cell therapy is that deriving immunologically-matched grafts for 
each patient would require generating, expanding and testing multiple iPS cell clones before 
obtaining one suitable for transplantation – a time-consuming and costly process.18 Contrary 
to the assumption that autologous iPS cell therapy eliminates the risk of immune rejection, a 
recent study showed that abnormal surface antigen expression in iPS-cell derived grafts 
induces a T cell-mediated immune response and tissue damage when transplanted in 
genetically identical recipients.19 Therefore, as with embryonic stem cell-based therapies, 
scientists would need to assess the stability and immunogenicity of each iPS cell clone (for 
which reliable and efficient assays are currently lacking) before transplantation. Due to these 
practical limitations, any future application of iPS cells, except for the select few who can 
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afford personalised therapy, may involve public stem cell banks with limited iPS cell lines 
representing sufficient genetic diversity to be compatible with the majority of the 
population. This raises important ethical concerns like resource allocation, donor consent 
and equity of biological access.20 
The absence of reliable animal models of Parkinson’s disease poses an additional barrier to 
translational research on iPS cell therapy. Although a translational gap exists whenever 
moving from pre-clinical to clinical testing of any medical intervention, in Parkinson’s disease 
research, the animal models are notoriously unreliable in predicting the patient response as 
they are toxin-based and exhibit acute dopaminergic depletions that fail to reflect the 
broader phenotype associated with the disease.21 For example, a novel class of drugs 
(monoamine uptake inhibitors) that had yielded promising results in toxin-based primate 
models produced limited functional improvement and many side effects when tested in 
patients with Parkinson’s disease.22Thus, animal models may have limited value in predicting 
the safety and efficacy of iPS cell therapy for patients.  
 Assuming iPS cell research is translated to the clinic, patients receiving therapy will require 
long-term monitoring due to the potential risk of serious, irreversible harm. As with 
embryonic stem cell-based therapies, grafts contaminated with undifferentiated cells.may 
cause tumour formation. This was tragically illustrated when a patient with ataxia 
telangiectasia developed a multifocal brain tumour after travelling overseas to receive 
neural stem cell “therapy” from an unlicensed Russian clinic.23 In response to the real risk of 
tumour formation, scientists have developed molecular imaging technologies to monitor 
grafts post-transplantation, but these currently lack the spatial resolution and sensitivity to 
be adopted in the clinic.24 Another strategy is inserting “suicide genes” to render cell lines 
susceptible to specific drugs that can be administered if the graft undergoes malignant 
transformation. However, this approach is untested in humans and the administered drugs 
may have non-specific toxicity.25 
Even if iPS cell therapy is shown to be safe, it cannot be assumed that it will be beneficial. As 
Parkinson’s disease is a multi-system disorder, symptoms like dementia and autonomic 
dysfunction which are caused by pathology in non-dopaminergic systems (and may be 
equally disabling as the motor symptoms) may not be improved by dopaminergic grafts 
alone.26 (The caveat is that a proposed treatment may not need to resolve all disease 
pathology to provide significant benefit and therefore merit use.) Also, the striatum has 
been targeted as the primary site of graft placement in virtually all previous animal studies, 
but this one-size-fits-all approach may be unsuitable for patients since the extent of 
dopaminergic depletionvaries between individuals and may involve extra-striatal regions.26 
Thirdly, grafted neurons may not fully integrate into the host neuronal circuitry, resulting in 
minimal functional improvement.27 Finally, the transplanted neurons may be susceptible to 
degeneration within the toxic environment of the diseased host brain.28 Although co-
transplanting neurons with neuroprotective molecules may hinder disease progression in 
the host brain and hence improve survival of the grafted cells, this approach remains 
unproven.29  
 
Ethical challenges 
The clinical testing of iPS cell therapy also raises significant ethical concerns given the 
substantial risks involved. First is the degree to which iPS cells must be shown to be safe in 
animal models before first-in-human studies are justified. Even where it is decided that 
human trials can begin, serious questions remain regarding subject recruitment, safety 
monitoring and consent. The high prevalence of dementia and state of dependency amongst 
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patients with Parkinson’s disease may limit their ability to make voluntary informed 
decisions about trial participation.30 The challenge of obtaining informed consent is 
compounded by the limited accuracy of the currently available clinical tests in assessing 
individual decision-making capacity.31 Alternative mechanisms will be required to increase 
participation of Parkinson’s disease patients in iPS cell therapy trials, including research 
advance directives and the identification of appropriate surrogate decision makers.32 The 
types of research to which surrogate decision makers may consent and the degree of risk to 
which they may subject the patient will also require clarification. 
Furthermore, as with gene therapy trials, subject selection for clinical trials of iPS cell 
therapy is invariably problematic. Recruiting patients with mild Parkinson’s disease may be 
preferable as they are more likely to benefit from the procedure and have the capacity to 
provide informed consent. However, subjecting relatively “healthy” patients to the uncertain 
risks of stem cell therapy is controversial as their condition is stable and manageable by 
other available treatment options.From an ethical standpoint, late-stage Parkinson’s disease 
patients lacking alternative treatment options should perhaps be recruited. Yet these 
patients may be susceptible to unrealistic expectations of efficacy, be unable to provide 
informed consent (although surrogates perhaps could) and be least likely to benefit from iPS 
cell therapy due to an advanced and potentially irreversible state of disease. 
 
Conclusion 
iPS cell technology clearly has the potential to transform the field of regenerative medicine 
and may one day deliver personalised therapeutics for a broad spectrum of chronic 
degenerative conditions, not merely limited to Parkinson’s disease. Preliminary results from 
animal studies have been promising and there are compelling reasons for public optimism 
and support for continued research. Initially, the benefit of iPS cell technology for medicine 
may be realised in disease modelling and screening of promising new drugs.33 However, we 
must recognise that the scientific, clinical and ethical issues facing iPS cell therapy are 
equally complex as those presented by embryonic stem cell-based approaches and are likely 
to delay its translation from bench to bedside. iPS cell therapy may indeed prove beneficial 
in the future, but we must be careful that the rush to embrace its potential is tempered with 
realism and not just a manifestation of “moral panic” over human embryonic stem cell 
research.   
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Text box 1. Glossary of key terminology  
 Stem cells - cells with the ability to divide indefinitely in culture and to give rise to specialised 
cells. Examples include adult somatic stem cells, embryonic stem cells and iPS cells. 
 
 Potency - the capacity of a stem cell to differentiate into different cell types. Embryonic stem 
cells and iPS cells are pluripotent and can differentiate into cells from all lineages of the 
body.  
 
 Embryonic stem cell – a type of pluripotent stem cell derived in the laboratory from the 
inner cell mass of a pre-implantation IVF embryo (blastocyst).  
 
 iPS cells – a type of pluripotent stem cell created in the laboratory from a non-pluripotent 
cell, typically an adult somatic cell, by reactivating the expression of specific genes 
associated with pluripotency. 
 
 Autologous transplantation - the transplantation of cells, tissues or organs which have been 
derived from a particular individual back into the same individual, with perfect 
immunological compatibility between donor and recipient.  
 
 Transgene - a segment of genetic material (DNA) that is transferred from one organism to 
another organism. 
 
 Stem cell tourism – where patients seek unproven stem cell-based treatments outside the 
accepted clinical trial framework. Many companies offering such “treatments” use 
aggressive online advertising strategies to recruit patients and charge considerable sums of 
money with little or no evidence of efficacy or safety. 
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Figure 1. Differentiation of patient-matched iPS cells into dopaminergic neurons for transplantation in Parkinson’s 
disease patients. (Reproduced in an abridged form from Kiskinis E, Eggan K. Progress toward the clinical application of 
patient-specific stem cells. J Clin Invest 2010; 120: 51-59.) 
 
